Kiadis Pharma NV is a clinical stage biopharmaceutical company based in the Netherlands. It focuses on research and development of cell-based immunotherapy products for the treatment of blood cancer (leukemia) and inherited blood disorders, such as thalassemia. The Company develops products that provide for Allodepleted T-cell ImmunotheRapeutics (ATIR) and are based on the Theralux platform. The Company develops ATIR101 and ATIR201, which are designed to support the patientâ€™s newly transplanted immune system before it becomes fully functional. The Company's products address risks and limitations of hematopoietic stem cell transplantation (HSCT) in blood cancers, such as opportunistic infections, Graft-versus-Host-Disease (GVHD), cancer relapse and limited donor availability.